Comparative Pharmacology
Head-to-head clinical analysis: MEFENAMIC ACID versus ZORVOLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEFENAMIC ACID versus ZORVOLEX.
MEFENAMIC ACID vs ZORVOLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
ZORVOLEX (diclofenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
50 mg orally every 8 hours or 100 mg orally every 12 hours; maximum 200 mg/day.
None Documented
None Documented
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal elimination half-life of the dual-release formulation is approximately 6-7 hours. Clinical context: Allows twice-daily dosing for sustained analgesic effect.
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Renal excretion of metabolites and conjugates accounts for approximately 50% of the dose, with biliary/fecal elimination of the remainder. Less than 5% is excreted unchanged in urine.
Category D/X
Category C
NSAID
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."